0001415889-23-014404.txt : 20231018 0001415889-23-014404.hdr.sgml : 20231018 20231018162542 ACCESSION NUMBER: 0001415889-23-014404 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231016 FILED AS OF DATE: 20231018 DATE AS OF CHANGE: 20231018 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wingrove Theresa CENTRAL INDEX KEY: 0001510720 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 231332476 MAIL ADDRESS: STREET 1: IMMUNOGEN, INC. STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 4 1 form4-10182023_081031.xml X0508 4 2023-10-16 0000855654 ImmunoGen, Inc. IMGN 0001510720 Wingrove Theresa C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM MA 02451 false true false false SVP OF REGULATORY AFFAIRS 0 Common Stock 2023-10-16 4 M 0 158641 4.55 A 161452 D Common Stock 2023-10-16 4 M 0 33363 4.55 A 194815 D Common Stock 2023-10-16 4 S 0 192004 14.40 D 2811 D Stock Option (right to buy) 4.55 2023-10-16 4 M 0 158641 0 D 2030-02-07 Common Stock 158641 63659 D Stock Option (right to buy) 4.55 2023-10-16 4 M 0 33363 0 D 2030-02-07 Common Stock 33363 208406 D The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.10 to $14.69, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges. This option was granted on 2/7/2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years. On 2/7/2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. As of the transaction date, 75% of the awarded options are vested. /s/ Renee Lentini, Attorney-in-Fact 2023-10-18